Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 10/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23703360 | 1.00 | IDH2 (0.45) | IDH2KCNH2PRKCIPIK3CAIDH1 | |
| SCHEMBL3321777 | 0.91 | MAPK1 (0.46) | IDH2KCNH2PIK3CAIDH1MAPK1 | |
| SCHEMBL25140729 | 0.79 | KCNH2 (0.52) | IDH2KCNH2PRKCIPIK3CACHEK1 | |
| SCHEMBL26775804 | 0.78 | PRKCI (0.44) | PRKCIMAPK1 | |
| SCHEMBL13326581 | 0.78 | PRKCI (0.44) | PRKCIMAPK1 | |
| SCHEMBL30478386 | 0.72 | PIK3CA (0.49) | IDH2KCNH2PIK3CACHEK1CHEK2 | |
| SCHEMBL13334977 | 0.71 | BAZ2A (0.43) | KCNH2CHEK1MAPK1 | |
| SCHEMBL12526259 | 0.70 | IDH2 (0.50) | IDH2PIK3CAIDH1CHEK1MAPK1 | |
| SCHEMBL22895360 | 0.70 | PIK3CA (0.47) | IDH2PIK3CACHEK1MAPK1 | |
| SCHEMBL974801 | 0.69 | CHRM2 (0.44) | PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2025-10-07 | — | — | US | disclosed |
| EP-4574822-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2025-06-25 | — | — | EP | disclosed |
| CN-118702672-A | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-115335050-B | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20240124413-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2024-04-18 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| EP-4096661-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2022-12-07 | — | — | EP | disclosed |
| CN-115335050-A | Compounds and compositions for treating skin conditions | 卡玛瑞制药有限公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220332697-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2022-10-20 | — | — | US | disclosed |
| WO-2021154966-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021154966-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | IDH2 3938/4885KCNH2 988/4885PRKCI 2241/4885 |
| US-20240124413-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | RDX, HAX1, F12 | IDH2 3938/4885KCNH2 988/4885PRKCI 2241/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | IDH2 3938/4885KCNH2 988/4885PRKCI 2241/4885 |
| US-20220332697-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | RDX, HAX1, F12 | IDH2 3938/4885KCNH2 988/4885PRKCI 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.